BriaCell's Upcoming Presentation at SABCS 2025
Exciting developments are on the horizon for BriaCell Therapeutics Corp. as they gear up for the prestigious San Antonio Breast Cancer Symposium (SABCS) taking place in December 2025. This major event signals a pivotal moment for the clinical-stage biotechnology company, known for its commitment to pioneering novel immunotherapies aimed at transforming cancer care. At this significant symposium, BriaCell will showcase compelling data that highlights the safety and efficacy of their Phase 2 clinical trials, as well as promising findings from their ongoing Phase 3 study.
Key Highlights from the Presentations
BriaCell is set to present three crucial posters during the SABCS, focusing on key positive signals observed in their clinical trials. The forthcoming posters underline the robustness of the Phase 2 results, which have shown favorable safety and efficacy profiles. Additionally, the company will present insightful biomarker data that has emerged from both their Phase 2 trial and the pivotal Phase 3 study.
“The positive clinical findings and the distinctive biomarker insights bolster our optimism for the ongoing Phase 3 study in metastatic breast cancer,” remarked William V. Williams, MD, the President and CEO of BriaCell. This sentiment reflects the empowerment that their research offers not only to oncologists but also to the patients they serve. This information is critical as it allows for a better understanding of each patient's unique cancer profile and the corresponding treatment options available.
Ongoing Studies and FDA Designation
The ongoing pivotal Phase 3 study of Bria-IMT combined with CPI has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), marking a significant regulatory acknowledgment of the therapy’s potential. This designation aims to expedite the development and review process, reflecting the urgent need for innovative cancer therapies.
Insights from the Chief Scientific Officer
Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer, expressed the importance of the biomarker data collected through their trials. “Our biomarker data offers vital insights into the mechanism of action behind our novel immunotherapy. This knowledge is crucial in crafting more accurately targeted treatment methods for healthcare professionals and patients alike,” said Dr. Lopez-Lago.
Details of the Poster Presentations
The upcoming presentations at the SABCS are specifically designed to engage the medical community and highlight the innovative strides BriaCell is making in the field of cancer immunotherapy. Key presentations will include:
- Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Date/Time: December 10, 2025, from 12:30 PM to 2:00 PM CST - Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Date/Time: December 10, 2025, from 12:30 PM to 2:00 PM CST - Abstract Number: 1614
Presentation Number: PS2-09-03
Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Date/Time: December 10, 2025, from 5:00 PM to 6:30 PM CST
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is recognized for its pioneering work in developing innovative immunotherapies that are transforming approaches to cancer treatment. The company is dedicated to improving survival rates and clinical outcomes for patients with major unmet medical needs. By fostering cutting-edge research and driving promising therapies forward, BriaCell remains at the forefront of the fight against cancer. Their commitment is exemplified by their endeavor to deliver cell-based immunotherapies that meet the unique demands of cancer patients.
As they prepare for their presentations at the SABCS, BriaCell continues to front the fight against breast cancer with robust scientific data and a supportive community. With promising advancements under their belt, they are positioning themselves as a leader in cancer immunotherapy.
Frequently Asked Questions
What is the significance of the upcoming SABCS presentation for BriaCell?
The SABCS presentation is key for BriaCell as it showcases their clinical advancements and the promising findings from their Phase 2 and Phase 3 studies, which could lead to improved cancer treatment options.
What kind of data will BriaCell present at the symposium?
BriaCell will present data including safety and efficacy signals from their Phase 2 study, along with biomarker findings from their pivotal Phase 3 study.
What is the Bria-IMT regimen?
The Bria-IMT regimen is an immunotherapy protocol designed to enhance the body's immune response against cancer, which has garnered Fast Track Designation from the FDA for its potential in treating breast cancer.
Who is leading BriaCell Therapeutics Corp.?
William V. Williams, MD, serves as the President and CEO of BriaCell, driving the company's mission toward innovative cancer treatments.
How can one find out more information about BriaCell's research?
More information can be found on their official website, which details their research initiatives, clinical trials, and corporate updates.
